Research progress on the antitumor effects of harmine

Front Oncol. 2024 Mar 25:14:1382142. doi: 10.3389/fonc.2024.1382142. eCollection 2024.

Abstract

Harmine is a naturally occurring β-carboline alkaloid originally isolated from Peganum harmala. As a major active component, harmine exhibits a broad spectrum of pharmacological properties, particularly remarkable antitumor effects. Recent mechanistic studies have shown that harmine can inhibit cancer cell proliferation and metastasis through epithelial-to-mesenchymal transition, cell cycle regulation, angiogenesis, and the induction of tumor cell apoptosis. Furthermore, harmine reduces drug resistance when used in combination with chemotherapeutic drugs. Despite its remarkable antitumor activity, the application of harmine is limited by its poor solubility and toxic side effects, particularly neurotoxicity. Novel harmine derivatives have demonstrated strong clinical application prospects, but further validation based on drug activity, acute toxicity, and other aspects is necessary. Here, we present a review of recent research on the action mechanism of harmine in cancer treatment and the development of its derivatives, providing new insights into its potential clinical applications and strategies for mitigating its toxicity while enhancing its efficacy.

Keywords: Peganum harmala; antitumor effect; derivatives; harmine; mechanism of action; β-carboline alkaloid.

Publication types

  • Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Gansu Provincial Science and Technology Department Key R&D Program - Social Development Project (grant no. 23YFFA0067), Gansu Provincial Higher Education Innovation Fund Project (grant no. 2022A-071), Gansu Provincial Health and Industry Research Plan and Management Project (grant no. GSWSKY2020-60), Scientific Research and Innovation Fund Project of Gansu University of Chinese Medicine (grant no. 2019KC2D-1), General Project of the Affiliated Hospital of Gansu University of Chinese Medicine (grant no. gzfy-2022-07), Gansu Provincial Administration of Traditional Chinese Medicine, Open Project of Gansu Provincial Traditional Chinese Medicine Research Center (grant no. zyzx-2023-15), Project of the Gansu Provincial Science and Technology Department (Grant No. 18JR2FA002), the “National TCM Specialty Advantage Acupuncture Specialist” project funded by the Gansu Provincial Administration of Traditional Chinese Medicine, and National Natural Science Foundation of China (No. 82160129).